ESPE Abstracts

It is known that more checks of blood glucose, metabolic control of patients with type 1 suffering Dm improvement. Improved technology has made it possible to develop devices interstitial glucose control both blinded (retrospective) and open (in real time). The FREE STYLE free device is the latest appearance on the Spanish/European market. Although initially not seem indicated in <18 th, these are the a priori more could benefit from an improvement of metabolic control.

Objective: To evaluate the impact of the implementation of the use of free FREESTYLE in children with DM1 to 3.6 and 12 months after implantation. It is valued changes in HbA1c, hypoglycemia and hyperglycemia events. Satisfaction level of families.

Methods: DM1 children over 2 years with at least 6 months duration from debut. Use ‘off label’ device, informed consent. Control at baseline, 3.6 and 12 months after implantation voluntary use. Cost for families. Variables HbA1c, hypoglycemia events/month (moderate, requiring intervention), hyperglycemia/month (>250 mgr/dl) Study comparativo. IBM Stastistics SPSS 19.0., Nonparametric paired samples n<30. Health Survey Questionnaire SF-36 (Spanish and summarized).

Results: Twelve children (7♂), mean age 10.5 to (8–15.5). Previous HbA1c (DCA): 8.1% (6.4–8.8) needs: 0.72 IU/kg per day (0.45–0.88), sensitivity 168 mgr/dl per IU (135–280) and Survey 7.2 points (6–8). Hypoglycemic events/month 6.8,2 (5–15) hypoglycemic events/month 12 (10–32). After 3 months of use HbA1c (DCA): 7.7% (6.8–7.9) P: 0.38, hypoglycemic events/month 4.9 (3–8) Events hipeglucemia/month 8 (7–20) difference P: 0.03 95% CI (0.12–0.48). After 12 months of use HbA1c (DCA): 6.8% (5.2–7.5) P: 0.38, hypoglycemic events/month 2 (1–5) Events hipeglucemia/month 5 (4–8) differences P: 0.001 95% (0.001–0.1) Enc 8.5 points (7–9).

Conclusion: Improving quality of life perceived by parents, improved metabolic control, together with the relatively low cost of the measure defines the potential of this device, allowing even a medium-term decline in consumption of test strips.